Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report), retaining the price target of $12.00.
Ed Arce has given his Buy rating due to a combination of factors surrounding Acurx Pharmaceuticals’ development of ibezapolstat (IBZ) for treating Clostridioides difficile Infection (CDI). The Phase 3 program for IBZ is strategically designed to meet the requirements of both the FDA and EMA, with plans to conduct two non-inferiority trials comparing IBZ to vancomycin. These trials aim to demonstrate IBZ’s efficacy in achieving Clinical Cure and reducing CDI recurrence, which are crucial endpoints for regulatory approval.
Additionally, recent publications have highlighted IBZ’s unique effects on the gut microbiome, distinguishing it from other antibiotics. IBZ’s selective antimicrobial activity allows it to target C. difficile while sparing beneficial gut bacteria, a feature that could significantly reduce CDI recurrence rates. This selectivity is supported by preclinical studies and genomic analyses, which show that IBZ’s mechanism of action preserves gut health by allowing beneficial microbes to resist its effects. These promising attributes of IBZ, coupled with the strategic planning of its Phase 3 trials, underpin Ed Arce’s positive outlook and Buy rating for Acurx Pharmaceuticals.
According to TipRanks, Arce is a 5-star analyst with an average return of 15.9% and a 47.00% success rate. Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Akebia Therapeutics, and Pliant Therapeutics.
In another report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a $5.00 price target.